Clinical outcomes were found to be consistent among transplant-eligible patients with mantle cell lymphoma (MCL), irrespective of the chemoimmunotherapy induction regimen that was administered, according to results of a retrospective analysis.
The type of chemoimmunotherapy induction treatment did not appear to impact overall response rate (ORR; P
= .43), progression-free survival (PFS; P
>.67), and overall survival (OS; P
>.35) on multivariate analysis.
“Within the limits of a retrospective study and modest power for some comparisons, type of induction therapy did not influence ORR, PFS, or OS for transplant eligible patients with MCL,” the authors wrote in the article.
... to read the full story